sthakur January 13, 2021
Bacterial Vaginosis Market

 

DelveInsight has launched a new report on Bacterial Vaginosis Market

 

Bacterial Vaginosis (BV) also is referred to as nonspecific vaginitis, is a vaginal condition that can produce vaginal discharge and results from an overgrowth of certain kinds of bacteria in the vagina. In the past, the condition was called Gardnerella vaginitis, after the bacteria that were thought to cause the condition. However, the newer name, bacterial vaginosis, reflects the fact that there are a number of species of bacteria that naturally live in the vaginal area and may grow to excess, rather than a true infection with foreign bacteria, such as occurs with many sexually-transmitted disease (STDs).

 

Get a free sample copy- https://www.delveinsight.com/sample-request/bacterial-vaginosis-market

 

Bacterial Vaginosis market size by therapies, covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030

 

Bacterial Vaginosis Treatment

Solosec (secnidazole) is the first and only single-dose oral therapy for Bacterial Vaginosis. This product was approved by the US FDA in 2017. The approval of Solosec gave women the option of a single, well-tolerated, oral dose treatment for BV, a common infection which can have many health consequences. BV is also treated by other medications include metronidazole, clindamycin oral or vaginal suppositories, and metronidazole vaginal gel. Metronidazole is the most common antibiotic for BV.

 

Key companies of the report

  • Symbiomix Therapeutics
  • Starpharma Holdings Limited
  • IPRAD pharma
  • Dare Biosciences
  • Osel
  • Gedea Biotech

 

Bacterial Vaginosis Market Insights

High prevalence rate of the indication in the female population is expected to act as a driver for the BV drug market in 7MM region. BV is the most common type of vaginal infection affecting women aged between 15-44 years of age. BV is also highly prevalent in pregnant women. It is expected that around 15% of the pregnant women in the US suffer from BV.

The dynamics of Bacterial Vaginosis market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the disease, incremental healthcare spending across the world and expected the launch of emerging therapies during the study period of 2017-2030.

 

Bacterial Vaginosis Treatment Market

Current treatments of Bacterial Vaginosis are associated with unacceptably high recurrence (>50% within 6–12 months). Possible mechanisms for recurrence include reinfection from a sexual partner or endogenous source, persistence of BV-associated bacteria following treatment and failure to recolonize with desirable Lactobacillus spp.

Clinicians and researchers in the field consider it an urgent priority to develop new and innovative approaches to the management of BV in order to achieve high and sustained long-term cure rates, to develop effective prevention strategies and to reduce BV-associated squela.

To accomplish and meet these unmet needs the future of Bacterial Vaginosis treatment is continuing to incline toward combined topical and oral antimicrobial therapies as well as more novel approaches are which include approaches that aim to restore a woman’s “healthy” vaginal microbiome and maintain homeostasis are much needed to prevent recurrent BV and its sequela, including transmission and acquisition of HIV and adverse obstetric outcomes, such as preterm birth.

Companies like Dare Biosciences and IPRAD pharma, are coming up with novel therapeutic approaches that can entirely change the treatment landscape of Bacterial Vaginosis. If launched these emerging potential candidates could pose an adverse threat to current Bacterial Vaginosis market players, by means their potential to transform the standard of care for Bacterial Vaginosis patients.

 

Bacterial Vaginosis Market Report Scope

  • The report covers the descriptive overview of Bacterial Vaginosis, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Bacterial Vaginosis epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Bacterial Vaginosis are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Bacterial Vaginosis market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Bacterial Vaginosis market

 

Get a free sample copy- https://www.delveinsight.com/sample-request/bacterial-vaginosis-market

 

Table of content

  1. Key Insights
  2. Executive Summary of Bacterial Vaginosis
  3. Competitive Intelligence Analysis for Bacterial Vaginosis
  4. Bacterial Vaginosis Market Overview at a Glance
  5. Bacterial Vaginosis: Disease Background and Overview
  6. Patient Journey
  7. Bacterial Vaginosis Epidemiology and Patient Population
  8. Treatment Algorithm, Current Treatment, and Medical Practices
  9. Unmet Needs
  10. Key Endpoints of Bacterial Vaginosis Treatment
  11. Marketed Products
  12. Emerging Therapies
  13. Bacterial Vaginosis: Seven Major Market Analysis
  14. Attribute analysis
  15. 7MM: Market Outlook
  16. Access and Reimbursement Overview of Bacterial Vaginosis
  17. KOL Views
  18. Market Drivers
  19. Market Barriers
  20. Appendix
  21. DelveInsight Capabilities
  22. Disclaimer
  23. About DelveInsight

 

Get a free sample copy- https://www.delveinsight.com/sample-request/bacterial-vaginosis-market

 

Why should you buy this Bacterial Vaginosis report?

  • The report will help in developing business strategies by understanding trends shaping and driving the Bacterial Vaginosis market
  • To understand the future market competition in the Bacterial Vaginosis market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Bacterial Vaginosis in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Bacterial Vaginosis market
  • To understand the future market competition in the Bacterial Vaginosis market

 

Related Reports

 

You can check our latest blogs- DelveInsight Blog    

 

Contact us

Shruti Thakur

[email protected]

+91-9650213330

https://www.delveinsight.com/

LinkedIn | Facebook | Twitter

https://mmcthemonitor.com/